Trial design and radiographic outcomes in PsA IL-23 trials

By Tom Whitfield

November 2026 is the publication date for a JAAD article examining radiographic outcomes in IL-23 inhibitor trials for psoriatic arthritis. It appeared in the Journal of the American Academy of Dermatology, Volume 95, Issue 5. David Oberlin and Jesse Veenstra authored the paper.

What does the article examine?

The study frame is cross-trial interpretation, not a report of a newly enrolled patient cohort. Oberlin and Veenstra address radiographic findings across multiple IL-23 inhibitor studies, with trial design providing the explicit interpretive focus. Their title makes one methodological proposition clear: imaging results require context before clinicians compare them.

The citation does not supply the evidence needed for a numerical comparison. It leaves out:

• The IL-23 inhibitor names or total number of trials.
• Cohort size, demographic distribution, or baseline joint disease.
• Comparator treatment, dose, treatment duration, or follow-up schedule.
• The definition or timing of the radiographic outcome.
• Effect estimates, confidence intervals, significance values, or imaging-adjudication methods.

Those omissions prevent readers from ranking the agents or calculating a treatment effect. They also preclude conclusions about structural progression, imaging response, or the durability of any radiographic change.

Why does trial design matter?

Trial design is the article’s stated lens, but the citation does not identify which design variables Oberlin and Veenstra analyze. Readers cannot assume that the authors controlled for comparator choice, baseline disease, imaging schedules, or the rules used to classify radiographic change. Nor does the record establish whether every study used the same endpoint or assessment method.

That distinction matters because the title addresses outcomes “across” trials rather than findings from one controlled head-to-head study. A result observed in one protocol does not automatically provide a like-for-like comparison with another protocol. The article’s framing therefore directs attention toward comparability, although the citation gives no examples or conclusions about specific differences.

The available record also lacks the trial count needed to judge the breadth of that comparison. It provides no patient totals, study durations, geographic sites, or inclusion criteria. Without those details, the analysis could encompass either a broad clinical-trial review or a narrower methodological comparison; the citation does not resolve that question.

What can readers conclude?

The fully supported conclusion is limited: Oberlin and Veenstra published an article in November 2026 about interpreting PsA radiographic outcomes through trial design. The citation does not disclose whether they found favorable, unfavorable, neutral, or mixed results across the IL-23 inhibitor studies.

No numerical finding in the citation supports superiority, equivalence, or a particular imaging threshold. Readers also cannot assign a clinical recommendation to any IL-23 inhibitor from the available record. The publication establishes an interpretive topic and a methodological focus, but it does not reproduce the underlying analysis.

That restraint is necessary because a radiographic endpoint can carry different meaning under different trial conditions. The title identifies that problem; it does not specify the conditions or show how much they altered the results. Any stronger interpretation would require the article’s full text and its trial-level evidence.

What will make the comparison usable?

Readers will need a traceable account of the included studies and the design features used in the analysis. The decisive details are straightforward:

• Which IL-23 inhibitors and trials the article reviews.
• Which radiographic definitions and time points each trial used.
• Which baseline, comparator, and follow-up differences affect interpretation.
• Which effect estimates and uncertainty measures support each conclusion.

Without those elements, the article’s cross-trial message remains a methodological frame rather than a reproducible result. Going forward, its conclusions will be assessable only when readers can connect each radiographic finding to the trial design that produced it.